Who Paid My Doc
Amy Kleinhans
Nurse Practitioner, Adult Health Mesa, AZ Nurse Practitioner
NPI 1821441718 CMS profile 10752474
6750 E Baywood Ave, Mesa, AZ 85206
General payments
$59,982
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$26,863
Through program year 2025, Amy Kleinhans of Mesa, AZ is reported in the CMS Open Payments database as having received $59,982 across 443 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $26,863 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $13,761 | 96 | |
| 2024 | General | $9,916 | 102 | |
| 2023 | General | $17,275 | 94 | |
| 2022 | General | $13,538 | 96 | |
| 2021 | General | $5,492 | 55 |
Beside peers
- Amy Kleinhans
- Nurse Practitioner, Adult Health median
- Middle half of Nurse Practitioner, Adult Health
- National median
In program year 2025, general payments to Amy Kleinhans were reported at $13,761. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.
Show as a table
| Year | Amy Kleinhans | Nurse Practitioner, Adult Health median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $5,492 | $138 | $43–$438 | $132 |
| 2022 | $13,538 | $165 | $54–$494 | $149 |
| 2023 | $17,275 | $178 | $61–$549 | $160 |
| 2024 | $9,916 | $186 | $62–$575 | $164 |
| 2025 | $13,761 | $184 | $59–$580 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 19 drugsPart D claims
934
Drug cost
$467,480
Branded share of claims
52.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 225 | $327,423 | |
| Xarelto Rivaroxaban | Brand | 58 | $77,697 | |
| Multaq Dronedarone Hcl | Brand | 28 | $43,226 | |
| Propafenone Hcl Er Propafenone Hcl | Brand | 29 | $5,010 | |
| Flecainide Acetate | Generic | 66 | $3,013 | |
| Dofetilide | Generic | 16 | $2,421 | |
| Metoprolol Succinate | Generic | 120 | $2,316 | |
| Amiodarone Hcl | Generic | 109 | $1,582 | |
| Sotalol Sotalol Hcl | Brand | 62 | $1,410 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 34 | $856 |
The 10 drugs with the highest cost, of 19 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 18 billing codesPaid by Medicare
$62,502
Medicare patients
479
Services billed
1,307
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Atrial fibrillation | 75% | |
| Ischemic heart disease | 52% | |
| Arthritis | 47% | |
| Heart failure | 35% | |
| Chronic kidney disease | 31% | |
| Diabetes | 21% | |
| Cancer | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
443 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Adult Health in Arizona
Therese Sargent
Nurse Practitioner, Adult Health · Phoenix, AZ
Heather McCoy
Nurse Practitioner, Adult Health · Scottsdale, AZ
Jennifer Mylod
Nurse Practitioner, Adult Health · Glendale, AZ
Natalie Wilson
Nurse Practitioner, Adult Health · Phoenix, AZ
Michelle Taylor
Nurse Practitioner, Adult Health · Gilbert, AZ
Sherry Denton
Nurse Practitioner, Adult Health · Scottsdale, AZ
Related records
Nurse Practitioner, Adult Health in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Adult Health
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.